StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

2-Brom-12'-hydroxy-5'α-isobutyl-2'-isopropylergotaman-3',6',18-trionmonomethansulfonat

Bromocriptine Mesylate

HCID 31100
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
22260-51-1
Standard-SMILES
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O
InChIKey
NOJMTMIRQRDZMT-GSPXQYRGSA-N
Summenformel
C33H44BrN5O8S
Durchschnittliche Molmasse
750,7 g/mol
Monoisotopische Masse
749,2094

Überblick

Bromocriptine methanesulfonate is a methanesulfonate salt. It has a role as an antiparkinson drug. It contains a bromocriptine.

Namen und Bezeichner

Bevorzugter Name
Bromocriptine Mesylate
IUPAC
(6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
Lokaler Name
2-Brom-12'-hydroxy-5'α-isobutyl-2'-isopropylergotaman-3',6',18-trionmonomethansulfonat
Englischer Name
Bromocriptine mesylate
Summenformel
C33H44BrN5O8S
Molmasse
750.7

Namen und Synonyme

BROMOCRIPTINE MESYLATE22260-51-1Bromocriptine mesilatePravidelCyclosetBagrenBromocriptine methanesulfonateCB-154 mesylateCb-154 mesilate2-Bromo-alpha-ergocryptine mesylateDTXSID6020197FFP983J3OD
Weitere Namen anzeigen
BCTBRCBromocryptine mesylateBromocriptine-13C-d3 MesylateBromocriptine Mesylate (150 mg)cb-154Serono-Bagren
2-Bromoergocryptine MesylateNSC-755915DTXCID00197CHEBI:3182Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-Mesylate, BromocriptineRefChem:564242 Bromoergocryptine Mesylate

Datenbank-Bezeichner

CAS
22260-51-1
PubChem CID
31100

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
181 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
5
Schwere Atome
48
Formalladung
0
Komplexität
1.320

Experimentelle und physikochemische Eigenschaften

Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agonists; Ergot Alkaloids

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section244.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
192 · 192-196° (dec)
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: 0.8 mg/mL
Aggregatzustand
solid
pka
4.9 · 4.90(at 25℃)
Farbe
white
Wasserlöslichkeit
2 O: · H2O: 0.8mg/mLethanol: 23mg/mL
Merck
13 · 13,1400
BRN
4115238 · 4115238
Stabilität
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (45.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P273, P280, P301+P317, P304+P340, P317, P318, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 11 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationBromocriptine mesylate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.)-, monomethanesulfonate (salt): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (45.5%)

Toxikologische Informationen

Treatment · 1 Eintrag

Treatment of overdose consists of removal of the drug by emesis (if conscious), gastric lavage, activated charcoal, or saline catharsis. Careful supervision and recording of fluid intake and output is essential. Hypotension should be treated by placing the patient in the Trendelenburg position and administering I.V. fluids. If satisfactory relief of hypotension cannot be achieved by using the above measures to their fullest extent, vasopressors should be considered. (L1827)

Health Effects · 1 Eintrag

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion. Route of Elimination: Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney. Half Life: 2-8 hours

FDA Pharmacological Classification · 2 Einträge

BROMOCRIPTINE MESYLATE

Ergot Derivative [EPC]; Ergolines [CS]

MeSH Pharmacological Classification · 3 Einträge

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.

Drugs that bind to and activate dopamine receptors.

Verwendung und Herstellung

Uses · 1 Eintrag

For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome. Bromocriptine is a semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion and is used in the treatment of pituitary tumors, Parkinson's disease (PD),Hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes. Ergoline alkaloids occurs in various species of vines of the Convolvulaceae (morning glory) family and in some species of lower fungi. (L1918, L1934)

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 729201
HRID 729201als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID
DTXSID6020197
ChEMBL
CHEMBL1200503
ChEBI
CHEBI:3182
UNII
FFP983J3OD
EC Number
244-881-1
InChIKey
NOJMTMIRQRDZMT-JGYCFGIMSA-N
SMILES
N12[C@@H](CC(C)C)C(N3CCC[C@@]3([H])[C@]1(O)O[C@@](C(C)C)(NC(=O)[C@H]1CN(C3CC4=C(NC5C=CC=C(C4=5)C3=C1)Br)C)C2=O)=O.S(=O)(=O)(O)C |&1:1,11,13,16,23,r|
CAS Datenbank
22260 · 22260-51-1(CAS DataBase Reference)

A slight hypotensive effect may accompany bromocriptine treatment. Few cases of cerebrospinal fluid rhinorrhea have been reported in patients receiving bromocriptine for treatment of large prolactinomas. Bromocriptine use has been associated with causing or worsening psychotic symptoms and fibrosis of multiple organs. Ingestion of ergoline alkaloids is known to cause the disease ergotism. Ergotism occurs in two forms, gangrenous and convulsive, likely depending on the different kinds and amounts of ergoline alkaloids present. (A2913, L1827, L1934)

Exposure Routes · 1 Eintrag

Oral (L1934). Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.

Toxicity Summary · 1 Eintrag

The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Ergoline alkaloids have been shown to have the significant affinity towards the 5-HT1 and 5-HT2 serotonin receptors, D1 and D2 dopamine receptors, and alpha-adrenergic receptors. This can result in a number of different effects, including vasoconstriction, convulsions, and hallucinations. Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum. (A2914, A2915, A2916, A2941)

Signs and Symptoms · 1 Eintrag

Side effects of bromocriptine include nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion, constipation, diarrhea and drowsiness. Convulsive ergotism can cause painful seizures and spasms, diarrhea, paresthesias, itching, headaches, nausea and vomiting. Usually the gastrointestinal effects precede the central nervous system effects. As well as seizures there can be hallucinations and mental effects including mania or psychosis. Gangrenous ergotism causes dry gangrene as a result of vasoconstriction induced in the more poorly vascularized distal structures, such as the fingers and toes. Symptoms include desquamation, weak periphery pulse, loss of peripheral sensation, edema and ultimately the death and loss of affected tissues. (L1920, L1827)

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bromocriptine mesylate

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

F
3-10
wgk
3
ridadr
UN 3077 9 / PGIII
hs_code
29396900
RTECS-Nr.
KE1595000
risk_code
20/21/22
Toxizität
LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)
hazard_code
Xn
safety_code
22-24/25-36
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1
Anwendungen · 2 Einträge

BeschreibungBromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively). It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM). Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP. Formulations containing bromocriptine have been used in the treatment of Parkinson''s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.

VerwendenDopamine receptor agonist; derivative of the ergotoxin group of ergot alkaloids. Prolactin inhibitor; antiparkinsonian.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

12'-Hydroxy-5'α-isobutyl-2'-isopropylergotaman-3',6',18-trionN-Bromsuccinimid